



# The New England Journal of Medicine

Established in 1812 as The NEW ENGLAND JOURNAL OF MEDICINE AND SURGERY

Abstracts in the advertising sections

VOLUME 317

OCTOBER 22, 1987

NUMBER 17

## Original Articles

- Plasma Glycocalicin: An Aid in the Classification of Thrombocytopenic Disorders** ..... 1037  
 MARK H. STEINBERG, JOHN G. KELTON, AND BARRY S. COLLIER
- "Salt-Sensitive" Essential Hypertension in Men: Is the Sodium Ion Alone Important?** ..... 1043  
 THEODORE W. KURTZ, HAMOUDI A. AL-BANDER, AND R. CURTIS MORRIS, JR.
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant Recipients** ..... 1049  
 DAVID R. SNYDMAN AND OTHERS
- Intermittent Coronary Occlusion in Acute Myocardial Infarction: Value of Combined Thrombolytic and Vasodilator Therapy** ..... 1055  
 DAVID HACKETT, GRAHAM DAVIES, SERGIO CHIERCHIA, AND ATTILIO MASERI

## Medical Progress

- Aortic Dissection** ..... 1060  
 ROMAN W. DESANTIS, ROBERT M. DOROGHAZI, W. GERALD AUSTEN, AND MORTIMER J. BUCKLEY

## Seminars in Medicine of the Beth Israel Hospital, Boston

- Regulation of Insulin-Gene Expression: Implications for Gene Therapy** ..... 1067  
 RICHARD F SELDEN, MAREK J. SKOŚKIEWICZ, PAUL S. RUSSELL, AND HOWARD M. GOODMAN

## Case Records of the Massachusetts General Hospital

- A 61-Year-Old Man with Abdominal Pain and a Mass in the Right Side of the Abdomen** ..... 1076  
 JAMES M. RICHTER AND EDWARD J. GUTMANN

## Editorial

- Sodium Chloride and Blood Pressure** ..... 1084  
 MYRON H. WEINBERGER

## Sounding Board

- An End to Patchwork Reform of Health Care** 1086  
 ROBERT L. DICKMAN, AMASA B. FORD, JEROME LIEBMAN, SHARON MILLIGAN, AND ALVIN L. SCHORR
- The Medical Clerkship** ..... 1089  
 SHERMAN M. MELLINKOFF

## Correspondence

- Adrenal Grafts for Parkinson's Disease** ..... 1091
- Human Immunodeficiency Virus Viremia as a Prognostic Indicator in Homosexual Men with Lymphadenopathy Syndrome** ..... 1093
- Menopause and the Risk of Coronary Heart Disease in Women** ..... 1094
- Medical and Surgical Treatment for Unstable Angina** ..... 1095
- Fetal Hemoglobin in SIDS** ..... 1096
- Prenatal Diagnosis of Duchenne's Muscular Dystrophy** ..... 1097
- Simplified Calculation of Body-Surface Area** ..... 1098

- Book Reviews** ..... 1098

- Notices** ..... 1100

- Correction**  
**Changing Aspects of the Natural History of Valvular Aortic Stenosis** ..... 1100

Duchenne's muscular dystrophy. We suspect that several of our patients have an autosomal disease with the same phenotype as Duchenne's muscular dystrophy but with a different genetic defect.<sup>4</sup>

Whatever the cause, recombination is an important source of error in the use of DNA probes for genetic counseling of families with X-linked dystrophy. As with any diagnostic test, it is important to have reliable data on the accuracy of these probes if they are to be used clinically. On the basis of our information, the error rate with even the best probes is at least 7 percent.

KENNETH H. FISCHBECK, M.D.  
ALBERT W. RITTER  
Hospital of the  
University of Pennsylvania

Philadelphia, PA 19104

1. Goodfellow PN, Davies KE, Ropers H-H. Report of the committee on the genetic constitution of the X and Y chromosomes. *Cytogenet Cell Genet* 1985; 40:296-352.
2. Fischbeck KH, Ritter AW, Tirschwell DL, et al. Recombination with pERT87 (DXS164) in families with X-linked muscular dystrophy. *Lancet* 1986; 2:104.
3. Ott J. Estimation of the recombination fraction in human pedigrees: efficient computation of the likelihood for human linkage studies. *Am J Hum Genet* 1974; 26:588-97.
4. Fischbeck KH, Ritter A, Kunkel LM, et al. Genetic heterogeneity in Duchenne dystrophy. *Neurology* 1987; 37:Suppl 1:116.

The above letters were referred to the authors of the article in question, who offer the following reply:

*To the Editor:* Although we agree with Dove and colleagues that the normal distribution of creatine kinase levels has to be carefully considered when serum creatine kinase determinations are used to assign carrier status, we disagree with their opening statement that "the use of DNA probes for prenatal diagnosis of carrier status . . . relied, in the absence of an affected male, on measurement of serum creatine kinase activity." This is not true of the families presented in our paper. In both families that fell into this category, Families A and B, the maternal grandmothers of the male fetuses at risk were obligate carriers. One had two affected sons, and the other had an affected brother and an affected son. The task at hand was to determine by DNA analysis whether the pregnant woman had passed on her maternally derived, possibly mutant, or her paternally derived, normal Xp21 region to her fetus. The creatine kinase results were irrelevant to the diagnosis in both cases, especially since values in the normal range do not exclude carrier status.

Fischbeck and Ritter provide additional data on the frequency of recombination between the phenotype for Duchenne's muscular dystrophy and polymorphisms detected by intragenic probes, which agree with our conclusions that recombination within the gene is an important source of error. Their 7 percent error rate, however, appears to be based on the use of a single intragenic marker. As we pointed out in our paper and documented in the families in our study, this type of error can be avoided by using flanking DNA markers outside the gene in addition to intragenic markers. If the entire Xp21 haplotype is transmitted without apparent recombination, the risk of error is much lower than 7 percent. On the other hand, if haplotype analysis reveals a crossover event, the study is uninformative if the site of the mutation with respect to the site of the crossover point is unknown.

The issues discussed here, however, are superseded by a recent breakthrough with the cloning of the entire gene for Duchenne's muscular dystrophy.\* The 14-kb cDNA, when used as a molecular probe, detects deletions in at least 50 percent of all patients with Duchenne's or Becker's muscular dystrophy\* (and Darras BT, et al.: unpublished data), in contrast to the detection rate of less than 10 percent with previously available random DNA probes. These deletions represent the molecular basis of the disease and are detectable in affected males and in carrier females.

Thus, the cDNA method allows direct detection of the mutation in DNA, eliminating the need for linkage testing that is mostly applicable to large families and has inherent problems due to recombination. Most patients with Duchenne's muscular dystrophy are from families with a single proband, and in 50 percent of these, diagnosis of potential carriers and unborn fetuses can now be made accurately (Darras BT, et al.: unpublished data).

UTA FRANCKE, M.D.  
BASIL T. DARRAS, M.D.  
New Haven, CT 06510      Yale University School of Medicine

#### SIMPLIFIED CALCULATION OF BODY-SURFACE AREA

*To the Editor:* Values for body-surface area are commonly used in the practice of internal medicine, particularly to calculate doses of chemotherapeutic agents and index cardiac output and stroke volume. Body-surface area (BSA) is generally calculated from height (Ht) and weight (Wt), according to equations such as the classic 1916 Du Bois formula<sup>1</sup>:  $BSA (m^2) = 0.007184 \times Ht (cm)^{0.725} \times Wt (kg)^{0.425}$ . Although many nomograms based on such equations have been published, some are inaccurate,<sup>2</sup> and one is not always readily available when a determination must be made. At our institution, we use a simple, easy-to-remember modification of an equation by Gehan and George,<sup>3</sup> which requires the use of a calculator with a square-root key:

$$BSA (m^2) = \sqrt{\frac{Ht (in) \times Wt (lb)}{3131}}$$

or, in metric:

$$BSA (m^2) = \sqrt{\frac{Ht (cm) \times Wt (kg)}{3600}}$$

If a 73-inch-tall, 175-lb patient is used as an example, the key-stroke sequence on most calculators would be:

$$73 \times 175 = \div 3131 = \sqrt{\quad} = 2.02 m^2.$$

Although a slight degree of accuracy has been lost in making the above equations easy to remember, deviations from accepted values derived from other formulas<sup>1,3,4</sup> are generally less than 2 percent. We have made good clinical application of these equations and believe they may be of benefit to other physicians.

R.D. MOSTELLER, M.D.  
Akron, OH 44309      Akron City Hospital

1. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. *Arch Intern Med* 1916; 17:863-71.
2. Turcotte G. Erroneous nomograms for body-surface area. *N Engl J Med* 1979; 300:1339.
3. Gehan EA, George SL. Estimation of human body surface area from height and weight. *Cancer Chemother Rep* 1970; 54:225-35.
4. George SL, Gehan EA. Methods for measurement of body surface area. *J Pediatr* 1979; 94:342.

#### BOOK REVIEWS

##### NEUROANATOMY: AN ATLAS OF STRUCTURES, SECTIONS AND SYSTEMS

Second edition. By Duane E. Haines. 236 pp., illustrated. Baltimore, Urban and Schwarzenberg, 1987. \$22.50.

The second edition of this atlas has been considerably improved over the first, and new material has been added. Included are more